



LANGUAGES:

Italian, English

TECHNICAL SKILLS:

In-depth laboratory experience in Motorneuron diseases and cancer biology, preclinical models, and in vitro/in vivo techniques

Core Laboratory Competencies:

- Fluorescence cytological and histological imaging
- In Situ Hybridization [RNAscope]
- ELISA/ELLA Assay
- Fluorescence Enzymatic Assay
- RTqPCR
- Western Blot
- Rodent Models and In Vivo Procedures
- Patient-derived stem cells cultures
- Bacterial cell cultures
- Lentiviral vector transduction
- Scientific Writing and Grant Applications
- GLP-like Workflow and Laboratory Standards

Soft Skills:

Strong interpersonal and organizational skills, with a proven ability to work effectively both independently and in team settings. Highly reliable in meeting deadlines and managing multiple tasks simultaneously. Adaptable, proactive, and committed to continuous learning and collaboration in dynamic research environments.

PAOLO CABRAS

PHD STUDENT

EDUCATION:

UNIVERSITY OF PAVIA

Master's Degree in Neurobiology

- Final grade: 110L (28/04/2022)
- Experimental thesis: "Approfondimento del ruolo di GPNMB (glicoproteina B del melanoma non metastatico) come target terapeutico e biomarcatore in un modello di ratto di sclerosi laterale amiotrofica"

UNIVERSITY OF CAGLIARI

Bachelor's degree in Biology

- Final grade: 106/110 (17/04/2019)

LICEO SCIENTIFICO EUCLIDE (CA)

Scientific high school graduation -2015

JOB EXPERIENCES

- **PhD Student in Biomedical Science, University of Pavia, Italy. Project title: "Dissecting the molecular mechanisms regulating Gas6/AXL pathway and its role as a prognostic biomarker and therapeutic target in Glioblastoma Multiforme". October 2023- Present**
- **Post Graduate Researcher at Laboratory of Molecular and Cellular Neuropharmacology, Dr. Marco Peviani. University of Pavia, Pavia. September 2022 — 2023**
Main projects in which I was involved:
- **PNRR Project: "Messa a punto di Procedure e saggi innovativi in vitro e in vivo per la valutazione delle proprietà immunotossicologiche di nano particelle per gene delivery" January 2023-Present**
- **Collaboration with IDORSIA LTD (biopharmaceutical company) on the project: Investigation of neuroinflammatory responses in AAV9-CMV-TDP43 WPRE rat model of ALS.**
- **"Dissecting GPNMB as therapeutic target and biomarker in Amyotrophic Lateral Sclerosis"**
- **"Investigating Axl as new therapeutic target and potential biomarker for Amyotrophic Lateral Sclerosis"**

PUBLICATIONS ON INTERNATIONAL JOURNALS:

“Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer's disease mouse model” Rita Milazzo, Annita Montepeloso, Rajesh Kumar , Francesca Ferro, Eleonora Cavalca, Pietro Rigoni, **Paolo Cabras**, Yuri Ciervo, Sabyasachi Das, Alessia Capotondo, Danilo Pellin, Marco Peviani, Alessandra Biffi.
Paper published, Nature Communications, September 2024

"An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model" Marco Peviani, Sabyasachi Das, Janki Patel, Odella Jno-Charles, Rajesh Kumar, Ana Zguro, Tyler D Mathews, **Paolo Cabras**, Rita Milazzo, Eleonora Cavalca, Valentina Poletti, Alessandra Biffi.
Paper published, EMBO Molecular Medicine, March 2023

INTERNATIONAL AND NATIONAL CONGRESSES:

MND Symposium, December 2023, Basel, Poster Abstract.

“Increased ADAM 10/17 activity in an animal model of ALS: rationale for targeting ADAMs as a potential therapeutic target?” **Paolo Cabras** et al.

SINS September 2023, TURIN, Oral talk

“Increased ADAM 10/17 activity in an animal model of ALS: rationale for targeting ADAMs as a potential therapeutic target?” **Paolo Cabras** et al.

ENCALS, July 2023, BARCELONA, Poster Abstract.

“Increased ADAM 10/17 activity in an animal model of ALS: rationale for targeting ADAMs as a potential therapeutic target?” **Paolo Cabras** et al.

ENCALS, July 2023, BARCELONA, Poster Abstract.

"First evidence of altered Gas6-Axl signaling and correlation between sAXL blood levels and clinical decline in ALS." Peviani et al.

MND SYMPOSIUM, December 2022, Poster Abstract.

"First evidence of altered Gas6-Axl signaling and correlation between sAXL blood levels and clinical decline in ALS." Peviani et al.

FENS July 2022, PARIS, Poster Abstract

"Novel insights on the role and therapeutic potential of Glycoprotein nonmetastatic melanoma protein B (Gpnmb) in Amyotrophic Lateral Sclerosis." Mauro G. Spatafora et al. **Co-Author**.

AriSLA congress, November 2022, MILAN, Poster Abstract

“Increased ADAM 10/17 activity in an animal model of ALS: rationale for targeting ADAMs as potential therapeutic target?” **Paolo Cabras** et al.